<DOC>
	<DOCNO>NCT00017186</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine gemcitabine epirubicin treat patient malignant mesothelioma .</brief_summary>
	<brief_title>Gemcitabine Epirubicin Treating Patients With Malignant Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity gemcitabine epirubicin patient malignant pleural mesothelioma . - Determine toxicity regimen patient population . - Determine time progression overall survival patient treat regimen . - Assess quality life patient treat regimen . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute day 1 8 epirubicin IV day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 additional course beyond CR . Quality life assess baseline , prior course 3 , 3 month , 1 year . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignant pleural mesothelioma At least 1 measurable lesion accurately measure least one dimension At least 20 mm ( 2 cm ) diameter PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 3 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : LVEF least 50 % No history congestive heart failure No New York Heart Association class III IV heart disease Other : No uncontrolled infection No severe underlie disease would preclude study participation No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , noninvasive carcinoma , localized prostate cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation PRIOR CONCURRENT THERAPY : Chemotherapy : No 1 prior chemotherapy regimen malignant pleural mesothelioma No prior gemcitabine anthracyclines Other : No concurrent cimetidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
</DOC>